|
Post by sportsrancho on Jul 29, 2016 17:58:21 GMT -5
Sanofi profit down 11% as diabetes drug sales slip By Noemie Bisserbe Published: July 29, 2016 2:16 a.m. ET
SHARE PARIS---French drugmaker Sanofi SA on Friday reported a fall in second-quarter net profit, hurt by dwindling diabetes U.S. sales and adverse currency moves but said it still expected to meet its profit target this year.
The Paris-based drugmaker said net profit declined by 11% to EUR1.16 billion ($1.29 billion) for the three months through June from EUR1.3 billion a year earlier.
|
|
|
Post by centralcoastinvestor on Jul 30, 2016 0:35:16 GMT -5
Sanofi profit down 11% as diabetes drug sales slip By Noemie Bisserbe Published: July 29, 2016 2:16 a.m. ET SHARE PARIS---French drugmaker Sanofi SA on Friday reported a fall in second-quarter net profit, hurt by dwindling diabetes U.S. sales and adverse currency moves but said it still expected to meet its profit target this year. The Paris-based drugmaker said net profit declined by 11% to EUR1.16 billion ($1.29 billion) for the three months through June from EUR1.3 billion a year earlier. Ahh. Something to be happy about. I know it is a little twisted, but every time Sanofi makes a misstep or misses an earnings target, I get warm and fuzzy all over.
|
|
|
Post by akemp3000 on Jul 30, 2016 6:00:10 GMT -5
I agree. Sanofi has made their bed, now they're lying (sic) in it. I'm also guessing it's possible that Matt has been especially silent about Sanofi for a reason. He could be waiting on the 2.0 launch scripts to begin rising. This would strengthen their case that Sanofi sandbagged sales of Afrezza especially if MNKD does significantly better with a smaller and more focused sales force. It would then be the ideal time for Matt to call Sanofi on the carpet for a juicy settlement sum.
|
|
|
SNY
Jul 30, 2016 8:01:02 GMT -5
Post by peppy on Jul 30, 2016 8:01:02 GMT -5
|
|
|
SNY
Jul 30, 2016 11:17:22 GMT -5
kc likes this
Post by agedhippie on Jul 30, 2016 11:17:22 GMT -5
Looks like it is down to a drop in Lantus sales that was only partially offset by Toujeo. That is probably a combination of the European move to cheaper older insulins for Type 2 (moving to NPH) and the availability of biosimilars outside the US.
|
|
|
Post by mannmade on Jul 30, 2016 11:48:39 GMT -5
Looks like it is down to a drop in Lantus sales that was only partially offset by Toujeo. That is probably a combination of the European move to cheaper older insulins for Type 2 (moving to NPH) and the availability of biosimilars outside the US. And don't forget the Tresiba Effect. What a missed opportunity for Sanofi with AFREZZA...
|
|
|
Post by sportsrancho on Jul 30, 2016 13:19:55 GMT -5
Looks like it is down to a drop in Lantus sales that was only partially offset by Toujeo. That is probably a combination of the European move to cheaper older insulins for Type 2 (moving to NPH) and the availability of biosimilars outside the US. And don't forget the Tresiba Effect. What a missed opportunity for Sanofi with AFREZZA...
|
|
|
Post by lakers on Jul 30, 2016 13:20:25 GMT -5
Second-quarter sales of Apidra® were up 3.2% to €93 million, reflecting lower sales in the U.S. (down 11.8% to €30 million), which were more than offset by the performance in Emerging Markets (up 27.8% to €20 million). First-half sales of Apidra® were stable at €178 million.
[Emerging Markets could be a good opps for Afrezza w/ good partners.]
|
|
|
SNY
Jul 30, 2016 13:58:27 GMT -5
Post by op2778 on Jul 30, 2016 13:58:27 GMT -5
When SNY will fire his CEO? We can give them one for free (Hakan LOL). A little bit of humor. That said, i still think Afrezza+Tresiba and someone added in another board (Dexcom) can be the Holy Grail.
Hope sales keep rising and that someone at Novo open an eye too see What Afrezza is, the golden ticket.
|
|
|
Post by agedhippie on Jul 30, 2016 14:35:01 GMT -5
Outside the US Tresiba has been available for 3 years now and is established but still hugely outsold by Lantus. It's a nicer insulin but it suffers from not being that much better than the incumbent plus it is more expensive. The bright spot is Japan where it has 35% of the basal market three years after launch and is still growing.
Looking at the YTD NBRx (new to brand prescriptions) Tresiba has 8% of the market mostly by cannibalizing it's sibling Levemir (22%). Toujeo at 16% is rising very slowly while Lantus is dropping slowly at 45% so it's probably shedding market to Toujeo. Interestingly NPH still makes up around 9% of the NBRx which is just scary in this day and age. The growth in the market of 3% looks like it mostly went to Tresiba.
The Japanese numbers are very interesting and I am curious to know why we are seeing that. Maybe it could be applicable to Affrezza. I think there was a Japanese partner at one point in the past as well.
|
|
|
Post by kball on Jul 30, 2016 17:37:45 GMT -5
Looks like it is down to a drop in Lantus sales that was only partially offset by Toujeo. That is probably a combination of the European move to cheaper older insulins for Type 2 (moving to NPH) and the availability of biosimilars outside the US. And don't forget the Tresiba Effect. What a missed opportunity for Sanofi with AFREZZA...Wasn't Matt from down under the first to alert us to the powerful tresiba/afrezza combo vs anything else? Thinking Mike C and that Matt should have some important conversations soon if they haven't
|
|
|
Post by sla55 on Jul 30, 2016 18:27:21 GMT -5
|
|
|
SNY
Jul 30, 2016 19:54:02 GMT -5
Post by thekindaguyiyam on Jul 30, 2016 19:54:02 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
SNY
Jul 30, 2016 20:02:16 GMT -5
peppy likes this
Post by Deleted on Jul 30, 2016 20:02:16 GMT -5
u r not missing something. u r missing everything. that $15 is after insurance pays ex: if your insulin is partially or not all covered , you will have to pay out of your pocket $x and that $x can be reduced to $15 using the savings card but the card will pay not by more than 500( afrezza has 150 i think ) tresiba : Pay no more than $15 out of pocket. Novo Nordisk will pay up to $500 of your co-pay for each of your first 24 prescription fills. This savings offer is valid for a maximum of 24 prescription co-pay benefits per patient. If your co-pay is already $15 or less, this offer does not apply Offer not valid for prescriptions paid in part or full by any federally or state-funded programs, including but not limited to Medicare or Medicaid, Medigap, VA, DOD, TRICARE, and where prohibited by law. The federal employee health benefits program is not a federal or state government health care program for purposes of this savings program
You must have a co-payment. Not valid for cash payments for your prescriptions
|
|
|
SNY
Jul 30, 2016 20:34:28 GMT -5
lakon likes this
Post by peppy on Jul 30, 2016 20:34:28 GMT -5
And don't forget the Tresiba Effect. What a missed opportunity for Sanofi with AFREZZA...Wasn't Matt from down under the first to alert us to the powerful tresiba/afrezza combo vs anything else? Thinking Mike C and that Matt should have some important conversations soon if they haven't Agreed kball. Matt's video's, he is a producer. Matt b understanding of insulin is superior. He was able to teach me. afrezzadownunder.com/ (I wonder if Matt would do the commercial advertisement.)
|
|